{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:14:56Z","timestamp":1794507296072,"version":"4.9.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durable responses after receiving lower CAR-T cell doses, the mechanisms underlying efficacy at these limited cell numbers remain poorly understood. To address this, we performed deep phenotyping of anti-CD19 CAR-T cell products and their corresponding leukapheresis starting materials from a phase I\/II dose-escalation trial. We also report the primary and secondary clinical outcomes of the diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma cohorts of the HD-CAR-1 basket trial (NCT03676504; EudraCT 2016-004808-60). Patients responding to low-dose CAR-T therapy showed dose-dependent enrichment of functional effector and effector memory-like CAR-T cells. The absolute number of these cells emerged as a robust biomarker of therapeutic response, valid across dose levels and CAR-T targets. Effective low-dose products were associated with high T-cell numbers and T-cell-supportive myeloid states in leukapheresis materials, whereas regulatory myeloid states promoted dysfunctional CAR-T cells and treatment failure. Our study provides insights into the phenotype, mechanisms, and biomarkers of CAR-T cells that drive therapeutic responses at low doses, with medical and socioeconomic implications.<\/jats:p>","DOI":"10.1038\/s41467-026-76068-4","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:45:01Z","timestamp":1785357901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A distinct CAR-T cell phenotype mediates therapeutic response at limited doses"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-0369","authenticated-orcid":false,"given":"Schayan","family":"Yousefian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luisa","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Minafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8851","authenticated-orcid":false,"given":"Patrick","family":"Derigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5260-6392","authenticated-orcid":false,"given":"Sarah","family":"Gr\u00e4\u00dfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arik","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta M.","family":"Demel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7547-1222","authenticated-orcid":false,"given":"Julian","family":"Liebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"R\u00f6themeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Pupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta E.","family":"H\u00f6pken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-0506","authenticated-orcid":false,"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-6947","authenticated-orcid":false,"given":"Antonia","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-7049","authenticated-orcid":false,"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1509","authenticated-orcid":false,"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-2051","authenticated-orcid":false,"given":"Simon","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"76068_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y. & Wu, M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm. Sin. B 8, 539\u2013551 (2018).","journal-title":"Acta Pharm. Sin. B"},{"key":"76068_CR2","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front. Immunol. 13, 927153 (2022).","journal-title":"Front. Immunol."},{"key":"76068_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76068_CR4","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325\u2013332 (2022).","journal-title":"Nat. Med."},{"key":"76068_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"76068_CR9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"76068_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"76068_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"76068_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic Lupus Erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815\u2013818 (2023).","journal-title":"Lancet"},{"key":"76068_CR19","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A-C Pecher","year":"2023","unstructured":"Pecher, A.-C. et al. CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329, 2154\u20132162 (2023).","journal-title":"JAMA"},{"key":"76068_CR20","doi-asserted-by":"crossref","unstructured":"Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D. & Fricke, S. CAR T cells for treating autoimmune diseases. RMD Open 9, (2023).","DOI":"10.1136\/rmdopen-2022-002907"},{"key":"76068_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"76068_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. MED 5, 550\u2013558.e2 (2024).","journal-title":"MED"},{"key":"76068_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR25","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi, A. et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 14, 1113882 (2023).","journal-title":"Front. Immunol."},{"key":"76068_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","volume":"7","author":"HE Stefanski","year":"2023","unstructured":"Stefanski, H. E. et al. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 7, 541\u2013548 (2023).","journal-title":"Blood Adv."},{"key":"76068_CR27","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood.2019002258","volume":"134","author":"EA Chong","year":"2019","unstructured":"Chong, E. A. et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood 134, 1873\u20131875 (2019).","journal-title":"Blood"},{"key":"76068_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-136136","volume":"136","author":"CA Jacobson","year":"2020","unstructured":"Jacobson, C. A. et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (Axi-Cel) in relapsed\/refractory large B cell lymphoma (R\/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood 136, 2\u20133 (2020).","journal-title":"Blood"},{"key":"76068_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek, D. F. et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy 18, 893\u2013901 (2016).","journal-title":"Cytotherapy"},{"key":"76068_CR30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Investig. 129, 2123\u20132132 (2019).","journal-title":"J. Clin. Investig."},{"key":"76068_CR31","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"76068_CR32","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"76068_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/bloodadvances.2021006563","volume":"7","author":"E Bourbon","year":"2023","unstructured":"Bourbon, E. et al. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 7, 744\u2013755 (2023).","journal-title":"Blood Adv."},{"key":"76068_CR34","doi-asserted-by":"publisher","first-page":"1004703","DOI":"10.3389\/fimmu.2022.1004703","volume":"13","author":"N Worel","year":"2022","unstructured":"Worel, N. et al. The frequency of differentiated CD3\u2009+\u2009CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. Front. Immunol. 13, 1004703 (2022).","journal-title":"Front. Immunol."},{"key":"76068_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","volume":"8","author":"C Carniti","year":"2024","unstructured":"Carniti, C. et al. Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma. Blood Adv. 8, 1968\u20131980 (2024).","journal-title":"Blood Adv."},{"key":"76068_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med. 30, 507\u2013518 (2024).","journal-title":"Nat. Med."},{"key":"76068_CR37","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2024024381","volume":"144","author":"K Maurer","year":"2024","unstructured":"Maurer, K. et al. Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood 144, 2490\u20132502 (2024).","journal-title":"Blood"},{"key":"76068_CR38","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","volume":"25","author":"Z-X Yan","year":"2019","unstructured":"Yan, Z.-X. et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma. Clin. Cancer Res. 25, 6995\u20137003 (2019).","journal-title":"Clin. Cancer Res."},{"key":"76068_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood.V128.22.221.221","volume":"128","author":"SA Grupp","year":"2016","unstructured":"Grupp, S. A. et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL). Blood 128, 221\u2013221 (2016).","journal-title":"Blood"},{"key":"76068_CR40","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"76068_CR41","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/trf.14110","volume":"57","author":"A Bersenev","year":"2017","unstructured":"Bersenev, A. CAR-T cell manufacturing: time to put it in gear. Transfusion 57, 1104\u20131106 (2017).","journal-title":"Transfusion"},{"key":"76068_CR42","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18609\/cgti.2018.105","volume":"4","author":"A Bersenev","year":"2018","unstructured":"Bersenev, A. & Kili, S. Management of \u2018out of specification\u2019 commercial autologous CAR-T cell products. Cell Gene Ther. Insights 4, 1051\u20131058 (2018).","journal-title":"Cell Gene Ther. Insights"},{"key":"76068_CR43","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"76068_CR44","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra3 (2016).","journal-title":"Sci. Transl. Med."},{"key":"76068_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"76068_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"76068_CR47","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"76068_CR48","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"76068_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Characteristics of premanufacture CD8\u2009+\u2009T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduct. Target. Ther. 8, 409 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76068_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4\u2009+\u2009CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"76068_CR51","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","volume":"8","author":"J-M Hoffmann","year":"2017","unstructured":"Hoffmann, J.-M. et al. Differences in expansion potential of naive chimeric antigen receptor t cells from healthy donors and untreated chronic lymphocytic leukemia patients. Front. Immunol. 8, 1956 (2017).","journal-title":"Front. Immunol."},{"key":"76068_CR52","doi-asserted-by":"publisher","first-page":"e026644","DOI":"10.1136\/bmjopen-2018-026644","volume":"9","author":"M-L Schubert","year":"2019","unstructured":"Schubert, M.-L. et al. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I\/II clinical trial protocol. BMJ Open 9, e026644 (2019).","journal-title":"BMJ Open"},{"key":"76068_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"M-L Schubert","year":"2023","unstructured":"Schubert, M.-L. et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J. Hematol. Oncol. 16, 79 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"76068_CR54","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","volume":"38","author":"P Derigs","year":"2024","unstructured":"Derigs, P. et al. Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study. Leukemia 38, 2419\u20132428 (2024).","journal-title":"Leukemia"},{"key":"76068_CR55","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"76068_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1084\/jem.20040863","volume":"201","author":"J Liu","year":"2005","unstructured":"Liu, J. et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201, 567\u2013577 (2005).","journal-title":"J. Exp. Med."},{"key":"76068_CR57","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/imcb.12405","volume":"99","author":"X Weng","year":"2021","unstructured":"Weng, X. et al. Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys. Immunol. Cell Biol. 99, 274\u2013287 (2021).","journal-title":"Immunol. Cell Biol."},{"key":"76068_CR58","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1182\/bloodadvances.2022008722","volume":"7","author":"K Le","year":"2023","unstructured":"Le, K. et al. Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity. Blood Adv. 7, 3952\u20133967 (2023).","journal-title":"Blood Adv."},{"key":"76068_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25764-4","volume":"12","author":"F-H Wang","year":"2022","unstructured":"Wang, F.-H. et al. Induction of type II collagen expression in M2 macrophages derived from peripheral blood mononuclear cells. Sci. Rep. 12, 21663 (2022).","journal-title":"Sci. Rep."},{"key":"76068_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).","journal-title":"Nat. Commun."},{"key":"76068_CR61","doi-asserted-by":"crossref","unstructured":"Bai, Z. et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. J. Immunother. Cancer 9, (2021).","DOI":"10.1136\/jitc-2020-002328"},{"key":"76068_CR62","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen, G. M. et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov 11, 2186\u20132199 (2021).","journal-title":"Cancer Discov"},{"key":"76068_CR63","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ccell.2023.08.015","volume":"41","author":"X Li","year":"2023","unstructured":"Li, X. et al. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41, 1835\u20131837 (2023).","journal-title":"Cancer Cell"},{"key":"76068_CR64","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","volume":"29","author":"ND Anderson","year":"2023","unstructured":"Anderson, N. D. et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat. Med. 29, 1700\u20131709 (2023).","journal-title":"Nat. Med."},{"key":"76068_CR65","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1158\/1078-0432.CCR-23-0178","volume":"29","author":"T Sar\u00e9n","year":"2023","unstructured":"Sar\u00e9n, T. et al. Single-cell RNA analysis reveals cell-intrinsic functions of CAR T cells correlating with response in a phase II study of lymphoma patients. Clin. Cancer Res. 29, 4139\u20134152 (2023).","journal-title":"Clin. Cancer Res."},{"key":"76068_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2643-3230.BCD-23-0212","volume":"5","author":"NJ Haradhvala","year":"2024","unstructured":"Haradhvala, N. J. & Maus, M. V. Understanding mechanisms of response to CAR T-cell therapy through single-cell sequencing: insights and challenges. Blood Cancer Discov 5, 86\u201389 (2024).","journal-title":"Blood Cancer Discov"},{"key":"76068_CR67","doi-asserted-by":"crossref","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","DOI":"10.1126\/sciadv.abj2820"},{"key":"76068_CR68","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"76068_CR69","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s43018-024-00768-3","volume":"5","author":"A Rezvan","year":"2024","unstructured":"Rezvan, A. et al. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat. Cancer 5, 1010\u20131023 (2024).","journal-title":"Nat. Cancer"},{"key":"76068_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","volume":"22","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. Mol. Ther. Methods Clin. Dev. 22, 377\u2013387 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"76068_CR71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","volume":"20","author":"E Noaks","year":"2021","unstructured":"Noaks, E., Peticone, C., Kotsopoulou, E. & Bracewell, D. G. Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Mol. Ther. Methods Clin. Dev. 20, 675\u2013687 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"76068_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart, C. M. et al. IL-4 drives exhaustion of CD8\u2009+\u2009CART cells. Nat. Commun. 15, 7921 (2024).","journal-title":"Nat. Commun."},{"key":"76068_CR73","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR74","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J. et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-celL Efficacy In Preclinical And Early Clinical Development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"76068_CR75","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2021-152028","volume":"138","author":"M-L Schubert","year":"2021","unstructured":"Schubert, M.-L. et al. Third-Generation Chimeric Antigen Receptor (CAR) T cells in patients with relapsed\/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) - results from the Heidelberg Trial 1 (HD-CAR-1 trial). Blood 138, 1734\u20131734 (2021).","journal-title":"Blood"},{"key":"76068_CR76","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","volume":"109","author":"FR Appelbaum","year":"2007","unstructured":"Appelbaum, F. R. et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109, 1810\u20131816 (2007).","journal-title":"Blood"},{"key":"76068_CR77","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760 (2018).","journal-title":"Blood"},{"key":"76068_CR78","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson, B. D. et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128, 2489\u20132496 (2016).","journal-title":"Blood"},{"key":"76068_CR79","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller, R. D. Simplified calculation of body-surface area. N. Engl. J. Med. 317, 1098 (1987).","journal-title":"N. Engl. J. Med."},{"key":"76068_CR80","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"XVII","author":"D Du BOIS","year":"1916","unstructured":"Du BOIS, D. CLINICAL CALORIMETRY. Arch. Intern. Med. (Chic) XVII, 863 (1916).","journal-title":"Arch. Intern. Med. (Chic)"},{"key":"76068_CR81","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"76068_CR82","doi-asserted-by":"crossref","unstructured":"Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. 2008 (2008).","DOI":"10.1088\/1742-5468\/2008\/10\/P10008"},{"key":"76068_CR83","doi-asserted-by":"publisher","first-page":"861","DOI":"10.21105\/joss.00861","volume":"3","author":"L McInnes","year":"2018","unstructured":"McInnes, L., Healy, J., Saul, N. & Gro\u00dfberger, L. UMAP: uniform manifold approximation and projection. JOSS 3, 861 (2018).","journal-title":"JOSS"},{"key":"76068_CR84","doi-asserted-by":"crossref","unstructured":"Venables, W. N. Modern Applied Statistics with S. (Springer, 2002).","DOI":"10.1007\/978-0-387-21706-2"},{"key":"76068_CR85","doi-asserted-by":"crossref","unstructured":"Zhao, J. et al. Detection of differentially abundant cell subpopulations in scRNA-seq data. Proc. Natl. Acad. Sci. USA. 118, (2021).","DOI":"10.1073\/pnas.2100293118"},{"key":"76068_CR86","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Use R!). 276 (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4"},{"key":"76068_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03334-3","volume":"25","author":"A Missarova","year":"2024","unstructured":"Missarova, A., Dann, E., Rosen, L., Satija, R. & Marioni, J. Leveraging neighborhood representations of single-cell data to achieve sensitive DE testing with miloDE. Genome Biol. 25, 189 (2024).","journal-title":"Genome Biol."},{"key":"76068_CR88","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76068_CR89","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"76068_CR90","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at https:\/\/doi.org\/10.1101\/060012 (2016).","DOI":"10.1101\/060012"},{"key":"76068_CR91","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Investig. 121, 1822\u20131826 (2011).","journal-title":"J. Clin. Investig."},{"key":"76068_CR92","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jcyt.2019.02.013","volume":"21","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy 21, 566\u2013578 (2019).","journal-title":"Cytotherapy"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76068-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:20:06Z","timestamp":1785522006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76068-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76068"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76068-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: S.H., S.Y., M-L.S., M.S. are listed as inventors for the international patent application WO 2024\/218318 from the Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Heidelberg University Hospital, Deutsches Krebsforschungszentrum Stiftung des \u00f6ffentlichen Rechts and HI-STEM gGmbH (Status: Application filed). The patent covers the application of the provided biomarker combination. Pa.D. has received an honorarium from MSD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7589"}}